Compare SHAZ & CSTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SHAZ | CSTL |
|---|---|---|
| Founded | 2024 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Medical Specialities |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 780.9M | 722.8M |
| IPO Year | 2025 | 2019 |
| Metric | SHAZ | CSTL |
|---|---|---|
| Price | $19.26 | $32.91 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 6 | 9 |
| Target Price | ★ $105.00 | $48.20 |
| AVG Volume (30 Days) | ★ 2.1M | 375.3K |
| Earning Date | 11-16-2026 | 11-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | $1,566,631.00 | ★ $344,229,000.00 |
| Revenue This Year | $7,470.09 | $12.74 |
| Revenue Next Year | $1,195.12 | $11.78 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 257.44 | 3.66 |
| 52 Week Low | $16.55 | $17.72 |
| 52 Week High | $97.48 | $44.28 |
| Indicator | SHAZ | CSTL |
|---|---|---|
| Relative Strength Index (RSI) | 34.73 | 43.98 |
| Support Level | $18.91 | $31.64 |
| Resistance Level | $27.85 | $34.23 |
| Average True Range (ATR) | 2.92 | 2.07 |
| MACD | 0.81 | -0.22 |
| Stochastic Oscillator | 4.38 | 13.45 |
SharonAI Holdings Inc is a neocloud operator, purpose-built to power the next generation of artificial intelligence (AI) and high-performance computing (HPC). The Company's infrastructure is architected from the ground up to meet the specific, intensive, and complex demands of modern AI training and inference workloads, machine learning, and Generative AI. Its services include: Sovereign AI Australia, GPU-as-a-Service, SHARON AI Cloud, SHARON AI Private Cloud, Virtual Private Clusters, HPC Servers, and SHARON AI Studio. The company's products are: SHARON AI Supercluster, GPU Fleet, Virtual Servers, Cloud Storage, and Machine Learning & Infrastructure. The Company operates in one operating segment, High Performance Compute Services (HPC).
Castle Biosciences Inc is a molecular diagnostics company. The group provides test solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus (BE), and uveal melanoma. The product portfolio of the company includes DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test; DecisionDx-SCC, a risk stratification test for cutaneous squamous cell carcinoma; MyPath Melanoma, a diagnostic GEP test for use in patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a test to predict future development of progression of high-grade dysplasia and/or esophageal cancer. The company derives revenues through the delivery of test reports for its molecular diagnostic tests.